Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?

Pediatrics

Volumn 118, Issue 3, 2006, Pages 1248-1251

  Safer, Daniel J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; META ANALYSIS; NOTE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SYSTEMATIC REVIEW; ADOLESCENT; AGE; CHILD; EDITORIAL; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANXIETY DISORDERS; CHILD; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33749079019     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0215     Document Type: Note

References (31)

1. US Food and Drug Administration. FDA approves Prozac for pediatric use to treat depression and OCD. January 3, 2003. FDA talk paper TO3-01. Available at: www.fda.gov/bbs/topics/ANSWERS/2003/ANS01187.html. Accessed March 29, 2005
2. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037
3. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205-1215
4. Shen Y; Center for Drug Evaluation and Research. Statistical reviews: application No. 18-936/SE5-064. 2003;10, 23. Available at: www.fda.gov/cder/foi/ nda/2003/18936S064_Prozac%20Pulvules_statr.pdf. Accessed April 4, 2005
5. Medicines and Healthcare Products Regulatory Agency. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents-summary of clinical trials. 2003. Available at: www.mhra.gov.uk/home/groups/pl-p/ documents/drugsafetymessage/con019472.pdf. Accessed July 16, 2005
6. Carpenter DJ, Lipschitz A, Fong R, Krulewicz S, Wilkinson C, Davies J. Is it appropriate to combine data from children and adolescents in pediatric MDD clinical trials? Poster presented at: New Clinical Drug Evaluation Unit annual meeting; Boca Raton, FL; June 8, 2005
7. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001:40:762-772
8. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288
9. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA. 2003;290:1033-1041
10. Emslie GJ, Findling R, Yeung, P, Kunz N. Venlafaxine XR in pediatric patients with major depressive disorder. Poster presented at: the American Academy of Child and Adolescent Psychiatry annual meeting; Washington, DC; October 23, 2004
11. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820
12. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2002;(2):CD002317
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed. Washington, DC; US Government Printing Office; 1976. DHEW Publication No. 76-388
14. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine study and followup. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:791-795
15. Geller DA, Biederman J, Stewart ES, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160:1919-1928
16. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004;43:1387-1396
17. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61:1153-1162
18. Mancini C, Van Ameringen M, Bennett M, Patterson B, Watson C. Emerging treatments for child and adolescent social phobia: a review. J Child Adolesc Psychopharmacol. 2005;15:589-607
19. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001;344:1279-1285
20. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42:415-423
21. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158:2008-2014
22. Geller DA, Biederman J, Reed ED, Spenser T, Wilens TE. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:36-44
23. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001;40:222-229
24. Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:1175-1181
25. Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. The effect of concomitant disorders in childhood depression predicting treatment response. Psychopharmacol Bull. 1990;26:235-238
26. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16:159-169
27. Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. Presented at: the joint meeting of the CDER Psychopharmacologic Advisory Committee and the Food and Drug Administration Pediatric Advisory Committee. Bethesda, MD; September 13-14, 2004. Available at: www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1.htmandwww.fda.gov/ohrms/ dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed August 1, 2005
28. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158:773-780
29. Carlson GA, Mick E. Drug-induced disinhibition in psychiatrically hospitalized children. J Child Adolesc Psychopharmacol. 2003;13:153-163
30. Rey JM, Dudley MJ. Depressed youth, suicidality and antidepressants. Med J Aust. 2005;182:378-379
31. Wagner KD, Jonas J, Findling RL, Ventura D, Saikall K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288